Effect of anti-S antibody titers on newly confirmed cases of COVID-19 in Korea: a community-based cohort study (K-SEROSMART Wave 2)
Open Access
- 28 October 2025
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-11
Abstract
Coronavirus disease 2019 (COVID-19) continues to impact populations globally, raising concerns about immunity levels and risks to high-risk groups despite the lifting of the global health emergency in May 2023. While studies have tracked seroprevalence, few have comprehensively assessed long-term antibody persistence and COVID-19 risk, particularly regarding immunity changes due to vaccination and infection. This study aimed to estimate the population prevalence of SARS-CoV-2-specific antibodies, including anti-spike (anti-S) and anti-nucleocapsid (anti-N) antibodies, and to assess the risk of newly confirmed COVID-19 infections in Korea in December 2022. We conducted a follow-up survey and blood testing of 9,945 participants in the Korea Seroprevalence Study of Monitoring of SARS-CoV-2 Antibody Retention and Transmission (K-SEROSMART) Wave 1. The K-SEROSMART Wave 2 study employed a staged approach through public health centers nationwide, using mobile web, telephone, and face-to-face surveys. The follow-up survey (Wave 2) was conducted between December 6 and 27, 2022, four months after the initial survey (Wave 1) conducted in August 2022. Participants self-reported sociodemographic characteristics and health status and provided blood samples for the analysis of anti-spike (anti-S) and anti-nucleocapsid (anti-N) antibodies via electrochemiluminescence immunoassay. Population prevalence estimates were weighted for demographic data. Multivariate Cox proportional hazards regression was used to assess the relationship between anti-S antibody titers from Wave 1 and new COVID-19 cases, adjusting for age and sex. A total of 7,528 individuals participated, yielding a follow-up rate of 74.9%. The population-adjusted prevalence rates of anti-S and anti-N antibodies were 98.5% and 70.0%, respectively. The percentage of newly confirmed COVID-19 cases was significantly higher in individuals with anti-S antibody titers below 2,000 U/mL, 2,000–3,999 U/mL, 4,000–5,999 U/mL, 6,000–7,999 U/mL, and 8,000–9,999 U/mL than in those with titers above 18,000 U/mL (hazard ratio [HR] = 9.9, 95% confidence interval [CI] = 7.2–13.5; HR = 8.1, 95% CI = 5.8–11.3; HR = 7.1, 95% CI = 5.0–10.1; HR = 4.2, 95% CI = 2.8–6.3; HR = 2.0, 95% CI = 1.2–3.3, respectively). This study demonstrated the feasibility of conducting a seroepidemiological cohort survey on COVID-19 using a nationally representative sample. Additionally, this study quantified anti-S antibody titer levels that are associated with reduced risk of new infections within a community.Keywords
This publication has 30 references indexed in Scilit:
- Antibody correlates of protection against Delta infection after vaccination: A nested case-control within the UK-based SIREN studyJournal of Infection, 2023
- Persistence of antibody responses to COVID-19 vaccines among participants in the COVID-19 Community Research PartnershipVaccine: X, 2023
- Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccineClinical Microbiology and Infection, 2023
- Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative ReviewInfectious Diseases and Therapy, 2023
- Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN studyJournal of Infection, 2022
- Reinfection with SARS‐CoV‐2 in general population, South Korea; nationwide retrospective cohort studyJournal of Medical Virology, 2022
- Trajectories of mental health status during the early phase pandemic in China: A longitudinal study on adolescents living in the community with confirmed casesPsychiatry Research, 2022
- Towards a population-based threshold of protection for COVID-19 vaccinesVaccine, 2021
- Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?Infection, 2021
- Evidence for antibody as a protective correlate for COVID-19 vaccinesVaccine, 2021